Loading…
← CockpitCompetitor Analysis › 002365.SZ Qianjiang Yongan Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Qianjiang Yongan Pharmaceutical Co., Ltd. Class A002365.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty
Momentum strong 65
Mkt cap
$523M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$27.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.4 pp
WACC 5.0%
Hurdle
+32 pp
Req g minus delivered
Close · CNYCN¥12.09
1D-3.0%
1W-1.1%
1M-7.8%
3M-4.2%
6M-11.8%
YTD-19.0%
1Y-31.1%
ATR %5.2%
52w lowhigh33.2% off high

What Qianjiang Yongan Pharmaceutical does

Employees: 912

Qianjiang Yongan Pharmaceutical at a glance

Size Qianjiang Yongan Pharmaceutical (002365.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $523M, the 3753rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.09 on 6 Nov 2026.

Performance Over six months the shares fell 11.8%, against -15.2% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 26.0% over the last twelve months (peer median +8.3%); the operating margin is 4.1% (peer median 1.2%).

Valuation It trades at 2.7× enterprise value to sales against a peer median of 2.2× (8th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.4 points below its cost of capital (5.0% WACC).

Relative performance

8010012011 May 202611 Aug 20266 Nov 2026002365.SZ 87Peer median 84
Six months, rebased to 100: Qianjiang Yongan Pharmaceutical against the median of its 20 peers (local-currency closes).

Qianjiang Yongan Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥979MCN¥779MCN¥835MCN¥969MCN¥1.46B
Revenue growth—-7%-14%-33%—
Gross profitCN¥207MCN¥117MCN¥150MCN¥236MCN¥462M
EBITDACN¥156MCN¥109MCN¥152MCN¥159MCN¥293M
Net incomeCN¥53.4MCN¥22.5MCN¥61.8M-CN¥12.3MCN¥140M
Free cash flowCN¥28.4MCN¥105MCN¥23.0MCN¥124MCN¥265M
Capital expenditureCN¥118MCN¥62.3MCN¥118MCN¥121MCN¥149M
Total debtCN¥3.22MCN¥9.96MCN¥46.0MCN¥47.3MCN¥47.2M

Quarterly statements and history in the cockpit →

Qianjiang Yongan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-30%-20%-10%6883504461000691300522600527000731000822300481300798605566600727002453LCFSSOTL603113603725121600KOP605399IOLCP002365.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Qianjiang Yongan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%2×4×6×6883504461000691300522600527000731000822300481300798605566600727002453LCFSSOTL603113603725121600KOP605399IOLCP002365.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qianjiang Yongan Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%6883504461600527LCFSSOTL603725KOP002365.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Qianjiang Yongan Pharmaceutical is the large dot.

Qianjiang Yongan Pharmaceutical competitors and peer comparison

How Qianjiang Yongan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qianjiang Yongan Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure002365.SZPeer medianRank in peer set
1-month return-7.8%-14.9%4th highest of 21
6-month return-11.8%-15.2%7th highest of 21
Distance from 52-week high-33.2%-44.7%8th highest of 21
Revenue growth (TTM)+26.0%+8.3%6th highest of 21
Operating margin4.1%1.2%10th highest of 21
EV / Sales2.7×2.2×8th most expensive of 21
Growth the price implies (Req g, 7 yrs)24.7%21.7%5th most demanding of 10
Growth delivered (Del g)-7.8%+7.0%2nd lowest of 10
Hurdle (Req g minus delivered)+32.4 pp+0.7 pp2nd most demanding of 10
ROIC minus cost of capital-2.4 pp-4.1 pp7th highest of 21
EV / EBITDA16.9×9.7×4th most expensive of 8
Net debt / EBITDA-5.3×-0.2×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Qianjiang Yongan Pharmaceutical 002365.SZChina$523M-12%+26%4%2.7×24.7%-7.8%
Jiangsu Feymer Technology 688350.SSChina$528M-14%-6%-1%3.0×30.2%+4.2%
DKS 4461.TJapan$530M-6%+31%15%0.9×5.3%+7.0%
Gansu Yatai Industrial Developent 000691.SZChina$516M-6%+29%0%5.9×n/an/a
Suzhou Sunmun Technology 300522.SZChina$534M-15%-5%-2%5.4×n/an/a
Jiangsu Jiangnan High Polymer Fiber 600527.SSChina$538M-30%+2%1%4.7×40.2%-14.6%
Sichuan Meifeng Chemical Industry 000731.SZChina$509M-14%-13%-6%0.5×n/an/a
Shandong Haihua 000822.SZChina$509M-36%-10%-33%1.3×n/an/a
Puyang Huicheng Electronic Material 300481.SZChina$540M-16%+11%9%2.1×n/an/a
Jiangsu Jinji Industrial 300798.SZChina$507M-33%+28%0%2.5×n/an/a
Hangzhou Flariant 605566.SSChina$505M-23%+22%8%2.5×n/an/a
Shandong Lubei Chemical 600727.SSChina$545M-15%+6%7%0.9×n/an/a
Great Chinasoft Technology 002453.SZChina$497M-27%-5%-54%8.2×n/an/a
Tidewater Renewables LCFS.TOCanada$495M+97%+24%20%2.4×-3.0%+126.4%
Savita Oil Technologies SOTL.NSIndia$491M+61%+26%10%1.0×17.5%+16.8%
Jinneng Science & Technology 603113.SSChina$559M-34%+6%-4%0.5×n/an/a
Guangdong Tianan New Material 603725.SSChina$489M+9%-12%2%1.5×21.7%+29.0%
Advanced Nano Products 121600.KSSouth Korea$565M-23%+33%12%5.5×28.1%+18.2%
Koppers KOPUnited States$567M-32%-5%10%0.8×-7.1%+2.4%
Jiangxi Chenguang New Materials 605399.SSChina$482M-30%+15%-9%2.8×n/an/a
IOL Chemicals & Pharmaceuticals IOLCP.NSIndia$569M+87%+19%9%2.1×29.8%+3.5%

Questions

Which companies are Qianjiang Yongan Pharmaceutical's closest peers?
The cockpit's peer set: Jiangsu Feymer Technology (688350.SS), DKS (4461.T), Gansu Yatai Industrial Developent (000691.SZ), Suzhou Sunmun Technology (300522.SZ), Jiangsu Jiangnan High Polymer Fiber (600527.SS), Sichuan Meifeng Chemical Industry (000731.SZ), Shandong Haihua (000822.SZ), Puyang Huicheng Electronic Material (300481.SZ).
Is Qianjiang Yongan Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.7× against a peer median of 2.2×, 8th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Qianjiang Yongan Pharmaceutical stock performed?
Over six months to 6 Nov 2026 the shares returned -11.8% against -15.2% for the median peer; over one year -31.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.